Vaccinogen to Present at 11th Annual BIO Investor Forum

FREDERICK, Md., Sept. 26, 2012 /PRNewswire/ -- Vaccinogen, Inc. announced today that the Company will present at the 11th Annual BIO Investor Forum on Tuesday, October 9, 2012 at 8:45 a.m. Pacific Time in San Francisco, CA.  Andrew Tussing, Vaccinogen co-founder, president and chief operating officer, will deliver the corporate presentation and business outlook.

About OncoVAX

OncoVAX® is the first cancer vaccine that both prevents cancer recurrence and addresses the diversity of cancer cells. Currently in a pivotal Phase III clinical trial, OncoVAX is designed to use a patient's own cancer cells to mobilize the body's immune system to prevent the return of colon cancer following surgery. Embracing the now widely recognized heterogeneity of cancer, OncoVAX uses a patient's own tumor to stimulate a broad immune response against the diversity of that patient's cancer cells. OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer. Within 35 days following surgery, patients are immunized with OncoVAX to prevent disease recurrence, which is incurable and occurs in up to 35% of patients. Patients are given three vaccinations once per week for three weeks, followed by a booster vaccination after six months. A previously completed Phase III trial published in The Lancet showed that OncoVAX cut the risk of recurrence by 61% in patients with Stage II colon cancer.

About Vaccinogen, Inc.

Vaccinogen, Inc. is a cancer vaccine company developing OncoVAX® as a treatment to prevent the recurrence of colon cancer and potentially other solid tumors. Vaccinogen has developed and patented a process that circumvents the extreme diversity of tumor cells by leveraging a patient's own live tumor cells to launch a broad immune response against cancer. OncoVAX has completed five clinical studies, including one Phase III trial with the optimum dose and regimen and will begin a pivotal Phase III trial under an FDA Special Protocol Assessment (SPA) classification by the end of 2012. More information is available at www.vaccinogeninc.com.

SOURCE Vaccinogen, Inc.

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.